Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

Area of Science:

• Biopharmaceutical Manufacturing
• Immunology
• Proteomics

Background:

• Host cell proteins (HCPs) are impurities in biotherapeutics, posing a potential immunogenicity risk.
• Effective removal of HCPs is critical during biopharmaceutical purification processes.
• Residual HCPs require careful assessment for safety and efficacy.

Purpose of the Study:

• To evaluate the immunogenicity risk associated with residual Chinese Hamster Ovary (CHO) cell-derived HCPs in monoclonal antibody (mAb) products.
• To assess the correlation between HCP levels, in vitro immune response, and in silico epitope prediction.
• To inform risk assessment and control strategies for HCP impurities in biotherapeutics.

Main Methods:

• Proteomic analysis using mass spectrometry to identify and quantify HCPs in various purification stages.
• In vitro immunogenicity assay using peripheral blood mononuclear cells (PBMCs).
• In silico algorithms to predict immunogenic potential based on amino acid sequences of HCPs.

Main Results:

• Samples with HCP levels up to 4000 ppm did not show increased immunogenicity risk compared to highly purified mAb samples.
• In silico analysis identified a few high-risk HCPs, but their concentrations in samples were insufficient to elicit an in vitro immune response.
• The purification platform effectively managed HCP levels, suggesting low immunogenicity risk.

Conclusions:

• High concentrations of HCPs in mAbs purified by this platform do not necessarily increase immunogenicity risk.
• In vitro and in silico methods provide valuable insights for HCP risk assessment.
• Findings support refined strategies for HCP control and risk management in biopharmaceutical development.